Aclarion, Inc. ACON
1.66 USD +0.12 (+7.51%)
At closeNov 9, 2026, 7:03 AM EST
1.69 +0.03 +1.81%
Pre-market · Nov 9, 7:03 AM ET
1.61 Day range 1.68
1.54 52-week range 9.36
- YTD
- -63.91%
- 1 year
- -77.90%
News
benzinga.com Aclarion Publishes CEO Letter; Notes Q3 Scan Volumes Up 85% YoY And Up 117% YtD Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the Company’s momentum and value-creating priorities for the quarter ended September 30, 2026."The third quarter was…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…
benzinga.com Aclarion Announces University Of Arizona College Of Medicine - Phoenix As New Clinical Site In Its CLARITY Trial University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical…
benzinga.com Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc Evaluation Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver…
benzinga.com Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatmentCLARITY is a prospective,…- benzinga.com Aclarion Launches Market Access Program In Partnership With PRIA Healthcare Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.Program aims to follow successful reimbursement wins in the UK…
benzinga.com Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
benzinga.com Aclarion Partners With Institute of Neuro Innovation on Back Pain Technology Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…- benzinga.com Aclarion Announces That Its Nociscan Technology Was Used In A New Research Study Exploring The Biological Factors Associated With Back Pain In Patients With Modic Type 1 Changes Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
benzinga.com SentinelOne To Rally Nearly 40%? Here Are 10 Analyst Forecasts For Friday Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. Stock targets and ratings also updated.- benzinga.com Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $7.5 Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $7 to $7.5.
benzinga.com Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale. Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse…- benzinga.com Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32)…
benzinga.com Aclarion Adds Lanman Spinal Neurosurgery As Clinical Site In CLARITY Trial Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volumeThe…- benzinga.com Aclarion Establishes Second Commercial Agreement With Weill Cornell Medicine; Deal Brings Nociscan To Weill Cornell Medicine And Och Spine At Newyork-Presbyterian/Weill Cornell Medical Center Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
- benzinga.com Aclarion Announces $2.5M Buyback Plan Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms…
- benzinga.com Aclarion Secures U.S. Patent Covering Machine Learning–Based Platform For Analyzing Magnetic Resonance Spectroscopy Data Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and…
- benzinga.com Aclarion Signs Commercial Agreement With Weill Cornell Medicine Over Access For Nociscan To Weill Cornell, Och Spine Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
- benzinga.com Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $7 Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the price target from $23 to $7.
- benzinga.com Aclarion Adopts 1-Year Shareholder Rights Plan To Protect Long-Term Value And Prevent Hostile Takeovers Aclarion, Inc. (NASDAQ:ACON, ACONW))) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the…
- benzinga.com Aclarion Expands AI Tool To Help Doctors Pinpoint Back Pain, Eyes Growth As More Hospitals Adopt Nociscan Technology Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
- benzinga.com Aclarion Expands Nociscan Availability In Los Angeles, Partners With Source Healthcare To Support Growth And Real-World Evidence Generation Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection…
benzinga.com Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028.
benzinga.com Aclarion Raises $10.4M, Extends Cash Runway Into 2028 Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…- benzinga.com Is the Market Bullish or Bearish on Aclarion Inc?
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Dow Edges Higher; US Economy Adds 50,000 Jobs In December 
benzinga.com WD-40 Posts Downbeat Q1 Results, Joins Olin, AXT And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial momentum.- benzinga.com Market-Moving News for January 8th ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…
benzinga.com Aclarion Announces Publication Of Featured Article Tech Update In Upcoming Special Pain Issue Of The International Journal Of Spine Surgery Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine…
benzinga.com Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $23 Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $22 to $23.
- benzinga.com Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.62) by 11.83 percent. This is a 99.8 percent increase over losses of $(1.50…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Aclarion Highlights Accelerating Growth, $13.3M Cash Balance, And AI-Driven Biomarker Validation Progress Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growthNociscan scan volumes increase +89%…
benzinga.com Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Aclarion Participated In The International Society Of Pain And Neuroscience Annual Meeting, Announces Use Of MR Spectroscopy For Identifying Biomarkers Of Discogenic Pain Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine. Nociscan converts…
benzinga.com Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Aclarion Begins Pivotal CLARITY Trial To Test Nociscan's Impact On Chronic Low Back Pain Surgeries Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help…